☰
✕

Plexiform neurofibromas treatment market

Plexiform Neurofibromas Treatment Market, by Drug Class (Selumetinib, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Others (Tricyclic Antidepressants, etc.)), by Patient Population (Pediatric, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample
  • Dec 2022
  • CMI5430
  • 415 Pages
  • Excel & Pdf
  • Pharmaceutical

Plexiform neurofibroma is the most common peripheral nerve sheath tumor of the orbit involving multiple nerve bundles, causing periorbital and orbital soft-tissue hypertrophy, primary or compensatory bony changes, and ocular abnormalities. Neurofibromatosis is a genetic disorder. It is inherited in an autosomal dominant pattern with variable penetrance. Plexiform neurofibromas develop during early childhood, often before the cutaneous neurofibromas have fully developed. The tumors in these disorders are usually noncancerous (benign), but sometimes can become cancerous (malignant).

The global plexiform neurofibromas treatment market is estimated to be valued at US$ 1,371.14 million in 2022 and is expected to exhibit a CAGR of 8.2% during the forecast period (2022-2030).

Figure 1. Global Plexiform Neurofibromas Treatment Market Share (%), by Drug Class, 2022

Global Plexiform Neurofibromas Treatment Market - Driver

Increasing adoption of inorganic strategies such as product approval by regulatory authorities such as Japanese Ministry of Health, Labour and Welfare (MHLW), is expected to drive the global plexiform neurofibromas treatment market over the forecast period. For instance, in September 2022, AstraZeneca, a biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW), approved Koselugo (selumetinib) in Japan for the treatment of plexiform neurofibromas with clinical symptoms, such as pain and disfigurement in paediatric patients three years of age and older.

Plexiform Neurofibromas Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,371.14 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 8.2% 2030 Value Projection: US$ 2,576.19 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Selumetinib, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Others (Tricyclic Antidepressants, etc.)
  • By Patient Population: Pediatric, Adult
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma
Growth Drivers:
  • Increasing strategies adopted by key market players such as product approval by regulatory authorities 
Restraints & Challenges:
  • Lack of approved drugs for the treatment of neurofibromatosis Type 1

Figure 2. Global Plexiform Neurofibromas Treatment Market Share (US$ Million), by Region, 2022

Global Plexiform Neurofibromas Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

The COVID-19 pandemic also had a negative impact on the global plexiform neurofibromas treatment market growth during COVID-19. Key stakeholders in the healthcare industry were impacted by the COVID-19 pandemic, which significantly disrupted clinical trial operations across the globe. Due to staff leaves, social-distance protocols, financial losses, and patient safety concerns, the investigative site's capabilities were disrupted. Companies that support the development of pharmaceuticals, including sponsors and contract research organizations, have shifted to remote working arrangements. Participation in clinical trials was affected due to COVID-19. According to half of clinics, existing clinical trial protocols were modified or postponed, and new research protocol delays or suspensions were reported. Even short-term delays in clinical trial research that devastated many neurofibromatosis families and slow Neurofibromatosis research aimed at developing new treatments, because the majority of Neurofibromatosis manifestations do not have approved treatment options.   

Global Plexiform Neurofibromas Treatment Market: Key Developments

Increasing adoption of inorganic strategies such as product approval by regulatory authorities such as European Commission is expected to drive the gloal plexiform neurofibromas treatment over the forecast period. For instance, in June 2021, AstraZeneca Plc., a pharmaceutical company, announced that the Koselugo (selumetinib) had been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 aged 3 years and above. The approval by the European Commission was based on positive results from the SPRINT Stratum 1 Phase II trial sponsored by the National Institute of Health's National Cancer Institute Cancer Therapy Evaluation Program. The SPRINT Phase II trial indicated that Koselugo (selumetinib) reduced the tumor volume in children, reducing the pain.  

Global Plexiform Neurofibromas Treatment Market: Restraint

Lack of approved drugs for the treatment of neurofibromatosis Type 1 is anticipated to hamper the growth of the global plexiform neurofibromas treatment market over the forecast period. For instance, in July 2022, according to the data published by the National Center for the Biotechnology Information, selumetinib developed by the AstraZeneca, a biopharmaceutical company, is the only drug approved by the U.S. Food and Drug Administration and European Commission for the treatment of pediatric patients aged 2 years and older suffering from neurofibromatosis type 1 who have inoperable, symptomatic plexiform neurofibromas (PN). Moreover, other symptomatic treatment are followed for the management of the disease.

Global Plexiform Neurofibromas Treatment Market - Key Players

Major players operating in the global plexiform neurofibromas treatment market include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary 
      • Market Snapshot, By Drug Class 
      • Market Snapshot, By Patient Population
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • PEST Analysis
    • PORTER’s Analysis
    • Key Developments
    • Brand Analysis
    • Merger and Collaboration Scenario
    • Epidemiology
    • Product Approvals/Launches
    • Treatment Algorithm
    • Treatment Option Analysis
    • Site of Activity (Mode of Action)
    • New Investments by Major Market Players
    • Manufacturer Revenue
    • Disease Awareness Programs
    • Healthcare Spending by Country
  4. Global Plexiform Neurofibromas Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Supply Side and Demand Side Analysis
    • COVID-19 Impact on Overall Healthcare Sector
    • Impact on Clinical Trials       
  5. Global Plexiform Neurofibromas Treatment Market, By Drug Class, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Selumetinib
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Anticonvulsants
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others (Tricyclic Antidepressants, etc.)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Plexiform Neurofibromas Treatment Market, By Patient Population, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Pediatric
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Adult
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Plexiform Neurofibromas Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million) 
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Plexiform Neurofibromas Treatment Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Canada
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Mexico
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Argentina
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Rest of Latin America
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.K.
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Germany
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Italy
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • France
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Spain
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Russia
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Rest of Europe
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • India
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Japan
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • ASEAN
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Australia
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • South Korea
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Rest of Asia Pacific
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Israel
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Rest of Middle East
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
        • North Africa
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • Central Africa
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
        • South Africa
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2017 - 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  9. Competitive Landscape
    • AstraZeneca
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceuticals Industries Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mallinckrodt Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • SpringWorks Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Alcaliber S.A
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Glenmark
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Amneal Pharmaceuticals LLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Aurobindo Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Apotex Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mylan N.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Solara Active Pharma Sciences Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Abbott
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Shanghai Kechow Pharma, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Endo Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Purdue Pharma L.P
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • NFlection Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Healx
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Array Biopharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About Us

*Browse 113 market data tables and 50 figures on "Global Plexiform Neurofibromas Treatment Market” - forecast to 2030

Detailed Segmentation:

  • Global Plexiform Neurofibromas Treatment Market, By Drug Class:
    • Selumetinib
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Anticonvulsants
    • Others (Tricyclic Antidepressants, etc.)
  • Global Plexiform Neurofibromas Treatment Market, By Patient Population:
    • Pediatric
    • Adult
  • Global Plexiform Neurofibromas Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Plexiform Neurofibromas Treatment Market, By Region:
    • North America
      • By Drug Class
        • Selumetinib
        • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • Anticonvulsants
        • Others (Tricyclic Antidepressants, etc.)
      • By Patient Population
        • Pediatric
        • Adult
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • Selumetinib
        • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • Anticonvulsants
        • Others (Tricyclic Antidepressants, etc.)
      • By Patient Population
        • Pediatric
        • Adult
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • Selumetinib
        • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • Anticonvulsants
        • Others (Tricyclic Antidepressants, etc.)
      • By Patient Population
        • Pediatric
        • Adult
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Selumetinib
        • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • Anticonvulsants
        • Others (Tricyclic Antidepressants, etc.)
      • By Patient Population
        • Pediatric
        • Adult
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • Selumetinib
        • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • Anticonvulsants
        • Others (Tricyclic Antidepressants, etc.)
      • By Patient Population
        • Pediatric
        • Adult
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Selumetinib
        • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • Anticonvulsants
        • Others (Tricyclic Antidepressants, etc.)
      • By Patient Population
        • Pediatric
        • Adult
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global plexiform neurofibromas treatment market during the forecast period (2022-2030)?

The global plexiform neurofibromas treatment market is estimated to be valued at US$ 1,371.14 million in 2022 and is expected to exhibit a CAGR of 8.2% between 2022 and 2030.

What are the major factors driving the market growth?

Increasing strategies adopted by key market players such as product approval by  regulatory authorities such as U.S.Food and Drug Administration, European Commission, and Japanese Ministry of Health, Labour and Welfare (MHLW), is expected to drive the market.

Which is the leading drug class segment in the market?

Selumetinib is the leading drug class segment in the market

What are the key factors hampering the growth of the market?

Lack of approved drugs for the treatment of neurofibromatosis Type 1 is expected to hamper the market

Which are the major players operating in the market?

Major players operating in the market include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now